342 results about "Dry eyes" patented technology

The invention relates to the technical field of artificial intelligence, and discloses a traditional Chinese medicine diabetes dry eye treatment difference evaluation system and method based on artificial intelligence, and the system comprises a four-diagnosis integrated module, a syndrome modeling module, an intelligent decision module, a curative effect feedback module, a knowledge base management module and a self-adaptive learning module. Multi-mode traditional Chinese medicine four-diagnosis data of tongue condition, pulse condition and eye diagnosis and modern physiological parameters of metabolic indexes are fused, a deep learning method is adopted for standardization processing, the problem that traditional Chinese medicine syndrome differentiation depends on subjective experience is solved, traditional Chinese medicine syndrome feature extraction of diabetes dry eye has objectivity and quantifiability, and the traditional Chinese medicine syndrome feature extraction efficiency is improved. The comprehensiveness and the accuracy of the diagnosis basis are improved; and the curative effect feedback module compares a prediction result with revival curative effect data in real time, and the knowledge base management module is linked to carry out case feature matching and strategy optimization, so that continuous optimization and long-term reliability of the treatment decision model are ensured.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

The invention discloses an image processing system and method for distinguishing xerophthalmia types, and relates to the technical field of image processing, and the method comprises the steps: firstly carrying out the standardization preprocessing of an original infrared meibomian gland image, further introducing an artifact perception link, and actively recognizing and positioning the interference regions, such as eyelash shielding and uneven illumination, in the image; and guiding the subsequent meibomian gland segmentation process by using the sensed artifact information, thereby realizing the accurate extraction of the meibomian gland form under the complex background. On the basis, multi-dimensional quantification is carried out on the precisely segmented gland form, and image features are converted into objective numerical indexes. And finally, carrying out comprehensive judgment on the numerical indexes by utilizing a decision tree model, and outputting standardized MGD severity grade. In this way, interference information brought by image artifacts can be intelligently suppressed, and therefore more robust and accurate MGD severity grading is achieved in a clinical image with poor quality.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

According to the xerophthalmia core index multi-task AI detection system, method and terminal provided by the invention, the xerophthalmia multi-modal image is collected and exclusive preprocessing is completed, and core index detection is carried out on the preprocessed image based on the xerophthalmia multi-index detection model, so that the xerophthalmia core index detection result is obtained. Outputting detection results such as meibomian gland deletion rate, tear film rupture time, staining classification, tear river height and blepharitis marginal inflammation classification; and dynamically adjusting the index result according to a calibration coefficient corresponding to the type of the data acquisition equipment, and finally generating a standardized detection report. A xerophthalmia multi-index detection model is constructed based on an improved U-Net3 + architecture, a dry eye feature enhancement encoder and a cross-scale feature fusion decoder are adopted, a customized multi-task detection head is matched, an inter-task attention collaboration mechanism is established, meanwhile, a preprocessing algorithm and a dynamic calibration mechanism matched with a dry eye image are designed, and the detection accuracy of the xerophthalmia is improved. And multi-index synchronous, high-precision and high-efficiency detection is effectively realized.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

A dry eye treatment device, having a roller, a holder, wherein the roller contacts and rolls over an eyelid in a plurality of directions in a treatment; a heating element to generate heat, wherein at least a portion of the heat is transferred to the roller; a temperature monitoring system, which has a thermal sensor and a temperature control circuit; and an electric power source. The roller is of a convex cylindrical or concave cylindrical shape. A method for dry eye treatment, of cleaning an eyelid with a first cleansing wipe; heating a roller to a predetermined temperature; applying thermally conductive gel between the roller and the eyelid; rolling the roller over the eyelid in a plurality of directions; and removing the thermally conductive gel and expressed debris with a second cleansing wipe; and further, increasing the temperature by an increment and repeating the treatment method.

This invention relates to the use of recombinant type III humanized collagen and compositions comprising thereof in the ocular field. The invention provides the use of recombinant type III humanized collagen in the preparation of products for the prevention and / or treatment of ocular inflammation, and compositions comprising recombinant type III humanized collagen, and the use of these compositions in the preparation of products for the prevention and / or treatment of ocular inflammation and / or dry eye. Recombinant type III humanized collagen and compositions comprising thereof can significantly promote the renewal and repair of corneal epithelial cells, while inhibiting the release of inflammatory mediators, strengthening the ocular tissue barrier, enhancing tear film stability, and relieving ocular inflammation and dry eye.

The use of an opioid molecule, the levorotatory and dextrorotatory enantiomers of (3S)-6,7-dimethoxy-3-[(5R)-4-methoxy-6-methyl-7,8-dihydro-5H-[1,3] dioxolo [4,5-glisoquinolin-5-yl]-3H-2-benzofuran-1-one, capable of CFTR modulation and of suppressing the degranulation of basophils and mast cells, for the treatment of dry eye and eyes suffering from allergies.

1. The name of the design product: dry eye near weak vision nursing instrument. 2. The use of the design product: for dry eye near weak vision nursing instrument. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

The present application relates to the field of traditional Chinese medicine, in particular to a composition, eye patch and preparation method thereof for preventing and treating eye dryness, blurred vision fatigue and dry eye, comprising a carrier vehicle and a matrix layer, selecting medicinal materials with the effects of improving eyesight and resisting oxidation, fermenting the medicinal materials with plant lactic acid bacteria, bacillus or yeast to decompose macromolecules into small molecule active substances and possibly produce new active metabolites, adopting temperature control during the fermentation process to avoid high temperature from destroying heat-sensitive components, compounding the fermented medicinal material extract with hyaluronic acid, menthol, carboxymethyl cellulose and glycerol to form an intelligent rheological regulation body, hyaluronic acid synergistically enhances the moisturizing effect with the fermented extract, carboxymethyl cellulose serves as a film-forming agent to ensure the stability of the matrix layer, and glycerol improves the moisturizing performance, adopting a green process of activation, fermentation, mixing, loading and sterilization, selecting plant fibers as the carrier vehicle, cutting and packaging after loading the matrix layer, and then sterilizing to ensure the safety and effectiveness of the product.

This application generally relates to stable peptide compositions and kits comprising low levels of buffering and chelating agents, and methods of using the same for the treatment of patients having moderate / severe or severe dry eye.

The invention relates to a product suitable for the treatment of tear film deficiency in dry eye disease and a method for manufacturing the product. The invention also relates to a product for use in the treatment of tear film deficiency in dry eye disease. The product according to the invention provides for an improved wound healing in dry eye disease and other pathologies.

The present application provides compositions and methods for treatment of ocular inflammatory conditions, dry eye diseases, and abnormal corneal neovascularization, using etiprednol. In one example, a composition is provided comprising a semi-fluorinated alkane compound such as, e.g., perfluorohexyloctane; and an additive selected from paraffin, propylene glycol diacetate (PGD), a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, phenethyl alcohol, ethanol, isopropanol, glycerol, propylene glycol, polyethylene glycol, n-butanol, or combinations thereof. Eye drops comprising the compositions are also provided. Methods of using the compositions are also provided and include methods for reducing one or more symptoms of ocular inflammatory conditions, dry eye diseases, or abnormal corneal neovascularization.

The invention belongs to the technical field of biomedicine, and relates to a novel application of 3-O-methyl chrysotoxin, in particular to an application of 3-O-methyl chrysotoxin in preparation of a medicine for treating xerophthalmia. The core of the 3-O-methyl chrysotoxin disclosed by the invention is that the 3-O-methyl chrysotoxin effectively relieves corneal epithelial cell injury induced by hyperosmosis and inhibits oxidative stress and proinflammatory factor release by activating an EGFR (Epidermal Growth Factor Receptor) signal channel. In-vitro and in-vivo experiments prove that the composition can remarkably enhance cell activity, reduce apoptosis and active oxygen accumulation and repair the steady state of a tear film. The compound is applied to preparation of xerophthalmia drugs and has important clinical value.

The present disclosure provides a novel polypeptide. Also provided is an ophthalmic composition for treating or preventing dry eye (DE) or DE associated disorders. Also provided is a method for treating or preventing DE or DE associated disorders, stimulating tears, stabilizing tear film or any combination thereof in a subject in need thereof, comprising administering to the subject an effective amount of the novel peptides. Also provided is a contact lenses care product comprising the novel peptides and the preparation method thereof.

The present invention provides methods for alleviating pain and discomfort associated with a dry eye condition; methods for alleviating pain and discomfort while minimizing at least one skin imperfection; and methods for alleviating pain and discomfort while facilitating wound healing. The methods involve administering to a subject in need thereof a composition comprising hyaluronan with high elasticity.

The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4 H-quinazolin-3-yl)-benzonitrile.

The invention discloses difunctional nano drug-loaded eye drops for xerophthalmia and a preparation method of the difunctional nano drug-loaded eye drops, and belongs to the field of pharmaceutical preparation technologies and ophthalmology pharmacy. The core of the invention is to construct a composite nanoparticle which has a core-shell structure and has long-acting adhesion lubrication and targeted control drug release functions. The preparation method comprises the following steps: firstly, encapsulating a hydrophobic immunosuppressant such as cyclosporine A in a biodegradable pad polymer matrix such as polylactic acid-glycolic acid copolymer (PLGA) by an emulsification-solvent evaporation method to form a drug-loaded polymer nano core; through the exquisite integrated design of the structure and the function, collaborative targeted therapy of two core pathological links of'tear film instability 'and'immune inflammation' of xerophthalmia is achieved, the bioavailability of the medicine is remarkably improved, the medication frequency and eye irritation are reduced, and the curative effect of xerophthalmia is improved. A more efficient and safer administration scheme with better patient compliance is provided for clinical treatment of xerophthalmia.

Controllers for dry eye treatment apparatus and methods are described herein which generally comprise a patch or strip affixed to the skin of the upper and / or lower eyelids to deliver heat to the one or more meibomian glands contained within the underlying skin. The treatment strip or strips include one or more strips configured to adhere to an underlying region of skin in proximity to one or both eyes of a subject such that the one or more strips allow for the subject to blink naturally without restriction from the one or more patches. A controller is in communication with the one or more strips and is programmable to monitor a temperature of the one or more strips to provide a treatment therapy above a threshold temperature of, e.g., 39° C., and below a maximum temperature of, e.g., 48° C., over a treatment period of 12 minutes.

The application provides a composition containing Omega 3, which comprises a conjugate formed by connecting Omega 3 and a PEDF-derived peptide. The PEDF-derived peptide is obtained by truncation on the basis of a full-length PEDF protein, and the amino acid sequence is shown as SEQ ID No. 1. The Omega 3 is EPA, and the conjugate is obtained by connecting the Omega 3 and the PEDF-derived peptide through a click chemistry method. The composition can promote eye health repair, especially the treatment and improvement of dry eye, and has a clinical application prospect.

Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and / or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

The application provides an eye Tibetan medicine composition, a preparation and a preparation method and application thereof, and relates to the technical field of dry eye. The eye Tibetan medicine composition contains 80-120 parts by weight of berberis bark extract and 80-120 parts by weight of Qinghai dracocephalum extract. The eye preparation is prepared by mixing the eye Tibetan medicine composition and a solvent. The eye preparation can repair ocular surface tissue damage caused by dry eye and restore the normal secretion function of lacrimal glands.

The application discloses a tri-substituted tetrahydroisoquinoline amide derivative with a novel structure or a pharmaceutically acceptable salt thereof, which is a compound shown in formula I. The compound has a strong inhibiting capacity on immune cell migration, the compound itself has high permeability and good water solubility, and can be used as an immune cell migration inhibitor and used for developing a medicine for treating ophthalmic diseases such as dry eye.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Disclosed herein is a system and method for treating dry eye disease / dry eye syndrome in a subject, the system including a controller and an energy signal generator. Further included is at least one energy applicator configured to receive the energy signal from the energy signal generator and to apply a first energy signal and a second energy signal different from the first energy signal to a periorbital region of the eye of the subject. Wherein the first energy signal is configured to heat meibomian glands of the eye to a predetermined temperature and the second energy signal is configured to heat collagenous fibers in the eye to a predetermined temperature.

The present invention relates to the use of the isoquinoline multifunctional ligand amino-7 triethoxy-4,5,6 oxo-1 dihydro-1,3 isobenzofuranyl-3)-1 methoxy-8 methyl-2 methylenedioxy-6,7 tetrahydro-2,3,4 isoquinoline or tritoqualine for the treatment of dry eye, meibomian gland dysfunction and lacrimal gland dysfunction.

Provided are an eye care composition containing L-ergothioneine and a preparation method therefor and use thereof. The eye care composition containing L-ergothioneine provided in the present application includes the following components: L-ergothioneine, taurine, sodium hyaluronate, plant essential oil, p-benzenediboronic acid, an osmotic pressure regulator and water for injection. The preparation method includes mixing the sodium hyaluronate and the water for injection to obtain solution A; mixing the solution A, the taurine, the L-ergothioneine and the p-benzenediboronic acid, and adjusting pH to 5-7.5 to obtain solution B; and mixing the solution B and the plant essential oil, adjusting osmotic pressure to 250-350 mOsm / (Kg·H2O) by adding the osmotic pressure regulator, performing filtration and sterilization, and sub-packaging, so as to complete the preparation method. Based on the particular components and their proportions in the technical solutions of the present application, the eye care composition containing L-ergothioneine is obtained with the high stability, anti-inflammatory effect, relief effect on eye fatigue, itchy eyes and dry eyes, and good moisturizing effect.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

Disclosed are methods of treating dry eye disease. More particularly, this disclosure relates to a method of treating dry eye disease comprising exposure of a palpebral conjunctiva of an eye followed by transconjunctival irradiation in the presence of a photosensitizer to initiate crosslinking in tarsal plate tissue underlying the palpebral conjunctiva.